Literature DB >> 20039394

Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.

Michael D Bond1, Mark E Panek, Zheru Zhang, Dana Wang, Promod Mehndiratta, Hui Zhao, Keith Gunton, Alex Ni, Michael L Nedved, Sudhir Burman, David B Volkin.   

Abstract

The evaluation of a dual wavelength size exclusion high performance liquid chromatography (DW-SE-HPLC) method with improved sensitivity to detect aggregates in a high concentration IgG1 monoclonal antibody formulation is presented. This technique utilizes ultraviolet detection at two different wavelengths to monitor the levels of monomer, aggregate, and fragments and was shown to have improved sensitivity for the detection aggregates and fragments compared to light scattering (LS) detection. After assay optimization including the use of column conditioning, the limit of quantitation for aggregates was determined to be 0.04% with essentially complete recovery of aggregates from the column (>99.5%). The DW-SE-HPLC method was used to evaluate the level of protein aggregates generated by different environmental conditions such as exposure to elevated temperatures/acidic pH or intense light. The detection and characterization of protein aggregates by DW-SE-HPLC was compared with an orthogonal biophysical technique (sedimentation velocity analytical ultracentrifugation, SV-AUC). A good overall correlation was observed for levels of monomer, aggregates (dimer and multimers), and fragments as measured by the two analytical techniques (e.g., 6.0% vs. 5.3% and 14% vs. 11% for dimeric aggregates generated by elevated temperature/acidic pH and light exposure, respectively). The stability profile of a high concentration IgG1 monoclonal antibody formulation was investigated under stressed storage conditions (40 degrees C over 3 months) using the DW-SE-HPLC method including the loss of monomeric species with the concomitant accumulation of both aggregates and fragments. The nature and composition of the aggregates (primarily noncovalent dimers) and fragments (primarily loss of Fab from an intact IgG1) formed during storage were further characterized by a combination of LS measurements and mass spectroscopy analysis of deglycosylated IgG1 samples isolated by preparative SE-HPLC. The combination of DW-SE-HPLC, SV-AUC, LS, and mass spectroscopy results provided a detailed overall understanding the monomer, aggregate, fragment degradation pathway(s) for a high concentration IgG1 monoclonal antibody formulation during storage. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20039394     DOI: 10.1002/jps.22034

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Structure and function of purified monoclonal antibody dimers induced by different stress conditions.

Authors:  Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

Review 2.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

3.  Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.

Authors:  Weiqiang Cheng; Elena Curti; Wanderson C Rezende; Clifford Kwityn; Bin Zhan; Portia Gillespie; Jordan Plieskatt; Sangeeta B Joshi; David B Volkin; Peter J Hotez; C Russell Middaugh; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

4.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

5.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

6.  Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance.

Authors:  Asha R Srinivasan; Sunday A Shoyele
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

7.  Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry.

Authors:  Subhashchandra Naik; Ozan S Kumru; Melissa Cullom; Srivalli N Telikepalli; Elizabeth Lindboe; Taylor L Roop; Sangeeta B Joshi; Divya Amin; Phillip Gao; C Russell Middaugh; David B Volkin; Mark T Fisher
Journal:  Protein Sci       Date:  2014-07-28       Impact factor: 6.725

Review 8.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines.

Authors:  Nathaniel R Maddux; Sangeeta B Joshi; David B Volkin; John P Ralston; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2011-06-06       Impact factor: 3.534

9.  Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.

Authors:  Jayant Arora; Yue Hu; Reza Esfandiary; Hasige A Sathish; Steven M Bishop; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2016-08-25       Impact factor: 5.857

10.  Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

Authors:  Mohammad A Alsenaidy; Solomon Z Okbazghi; Jae Hyun Kim; Sangeeta B Joshi; C Russell Middaugh; Thomas J Tolbert; David B Volkin
Journal:  J Pharm Sci       Date:  2014-04-16       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.